Karasahin, OmerKalkan, Irem AkdemirDal, TubaToplu, Sibel AltunisikHarputluoglu, MuratMete, Ayse OzlemKomur, Suheyla2024-08-042024-08-0420231307-58882757-7392https://doi.org/10.14744/hf.2022.2022.0043https://search.trdizin.gov.tr/yayin/detay/1178904https://hdl.handle.net/11616/92731Background and Aim: In chronic hepatitis B infection, antiviral therapy significantly reduces the incidence of complications. This study aimed to present real-life 12-month effectiveness and safety data for TAF.Materials and Methods: This Pythagoras Retrospective Cohort Study included patients from 14 centers in Turkiye. The study presents 12-month results of 480 patients treated with TAF as initial therapy or after switching from another antiviral drug.Results: The study shows treatment of about 78.1% patients with at least one antiviral agent (90.6% tenofovir disoproxil [TDF]). The rate of undetectable HBV DNA increased in both treatment-experienced and naive patients. In TDF-experienced patients, the rate of alanine transaminase (ALT) normalization increased slightly (1.6%) within 12 months, but the change was not statistically significant (p=0.766). Younger age, low albumin, and high body mass index and cholesterol were identified as risk factors for abnormal ALT after 12 months, but no linear relationship was detected. In TDF-experienced patients, renal and bone function indicators showed significant improvement three months after the transition to TAF and remained stable for 12 months.Conclusion: Real-life data demonstrated effective virological and biochemical responses with TAF therapy. After switching to TAF treatment, gains in kidney and bone functions were achieved in the early period.eninfo:eu-repo/semantics/openAccessHepatitis Breal lifetenofovir alafenamideArticle4261683725092610.14744/hf.2022.2022.00432-s2.0-85164340106N/A1178904WOS:001000795000004Q4